BLOG

Wednesday, March 3, 2021

Covaxin shows 81% efficacy in phase-3 trials, says Bharat Biotech

Firm is gearing up to produce 40 million doses a month. Two Bio-safety Level-3 facilities (which can deal with deadly and contagious viruses) have been set up, third is on the way

from Home Page https://ift.tt/308gA6m
via IFTTT
at
Labels: ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Omicron has cast a shadow of uncertainty on growth outlook: IndiGo CEO

However, the airline is stronger now when compared to situation in 2020 during the first wave of the pandemic, says Ronojoy Dutta from Com...